Bausch Health Companies Inc. (BHC) 10-Year Financial Performance & Capital Metrics

BHC • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsMulti-Therapeutic Specialty

AboutBausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Show more

Revenue $9.63B +9.9%
EBITDA $2.81B +26.3%
Net Income -$46M +92.2%
EPS (Diluted) -0.13 +92.0%
Gross Margin 71.1% +0.4%
EBITDA Margin 29.23% +14.9%
Operating Margin 16.06% +46.1%
Net Margin -0.48% +92.9%
ROE -
ROIC 5.56% +61.1%
Debt/Equity -
Interest Coverage 1.11 +53.6%

Technical Analysis

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.62%

5Y2.28%

3Y4.5%

TTM-12.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM303.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM151.76%

ROCE

10Y Avg1.21%

5Y Avg3.56%

3Y Avg4.5%

Latest7.22%

Peer Comparison

Multi-Therapeutic Specialty

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BHCBausch Health Companies Inc.	2.69B	7.26	-55.85	9.91%	4.38%	101.78%	46.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	10.44B	9.67B	8.72B	8.38B	8.6B	8.03B	8.43B	8.12B	8.76B	9.63B
Revenue Growth %	0.27%	-0.07%	-0.1%	-0.04%	0.03%	-0.07%	0.05%	-0.04%	0.08%	0.1%
Cost of Goods Sold+	2.45B	2.57B	2.55B	2.35B	2.35B	2.25B	2.39B	2.36B	2.56B	2.78B
COGS % of Revenue	0.23%	0.27%	0.29%	0.28%	0.27%	0.28%	0.28%	0.29%	0.29%	0.29%
Gross Profit+	8B	7.1B	6.18B	6.03B	6.25B	5.78B	6.04B	5.76B	6.2B	6.84B
Gross Margin %	0.77%	0.73%	0.71%	0.72%	0.73%	0.72%	0.72%	0.71%	0.71%	0.71%
Gross Profit Growth %	0.33%	-0.11%	-0.13%	-0.02%	0.04%	-0.08%	0.05%	-0.05%	0.08%	0.1%
Operating Expenses+	6.47B	7.67B	6.07B	8.41B	6.45B	5.1B	5.59B	5.31B	5.24B	5.3B
OpEx % of Revenue	0.62%	0.79%	0.7%	1%	0.75%	0.64%	0.66%	0.65%	0.6%	0.55%
Selling, General & Admin	2.7B	2.78B	2.58B	2.47B	2.55B	2.37B	2.49B	2.53B	2.9B	3.28B
SG&A % of Revenue	0.26%	0.29%	0.3%	0.3%	0.3%	0.29%	0.3%	0.31%	0.33%	0.34%
Research & Development	440M	469M	369M	442M	516M	485M	473M	530M	604M	634M
R&D % of Revenue	0.04%	0.05%	0.04%	0.05%	0.06%	0.06%	0.06%	0.07%	0.07%	0.07%
Other Operating Expenses	3.33B	4.42B	3.12B	5.5B	3.38B	2.25B	2.63B	2.25B	1.74B	1.38B
Operating Income+	1.53B	-566M	102M	-2.38B	-203M	676M	450M	454M	963M	1.55B
Operating Margin %	0.15%	-0.06%	0.01%	-0.28%	-0.02%	0.08%	0.05%	0.06%	0.11%	0.16%
Operating Income Growth %	-0.24%	-1.37%	1.18%	-24.37%	0.91%	4.33%	-0.33%	0.01%	1.12%	0.61%
EBITDA+	3.99B	2.3B	2.96B	435M	1.87B	2.5B	2B	1.85B	2.23B	2.81B
EBITDA Margin %	0.38%	0.24%	0.34%	0.05%	0.22%	0.31%	0.24%	0.23%	0.25%	0.29%
EBITDA Growth %	0.1%	-0.42%	0.29%	-0.85%	3.3%	0.34%	-0.2%	-0.08%	0.21%	0.26%
D&A (Non-Cash Add-back)	2.47B	2.87B	2.86B	2.82B	2.08B	1.82B	1.55B	1.39B	1.26B	1.27B
EBIT	2.64B	1.21B	555M	500M	1.34B	1.31B	1.71B	1.48B	1.62B	1.87B
Net Interest Income+	-1.56B	-1.83B	-1.83B	-1.67B	-1.6B	-1.52B	-1.42B	-1.45B	-1.3B	-1.35B
Interest Income	3.3M	8M	12M	11M	12M	13M	7M	14M	26M	33M
Interest Expense	1.56B	1.84B	1.84B	1.69B	1.61B	1.53B	1.43B	1.46B	1.33B	1.39B
Other Income/Expense	-1.68B	-1.87B	-1.84B	-1.77B	-1.63B	-1.61B	-1.47B	-583M	-1.35B	-1.38B
Pretax Income+	-155M	-2.44B	-1.74B	-4.15B	-1.84B	-934M	-1.02B	-129M	-390M	167M
Pretax Margin %	-0.01%	-0.25%	-0.2%	-0.5%	-0.21%	-0.12%	-0.12%	-0.02%	-0.04%	0.02%
Income Tax+	133M	-27M	-4.14B	-10M	-54M	-375M	-87M	83M	221M	239M
Effective Tax Rate %	1.73%	0.99%	-1.38%	1%	0.97%	0.6%	0.93%	1.74%	1.52%	-0.28%
Net Income+	-268.66M	-2.41B	2.4B	-4.15B	-1.78B	-559M	-948M	-225M	-592M	-46M
Net Margin %	-0.03%	-0.25%	0.28%	-0.49%	-0.21%	-0.07%	-0.11%	-0.03%	-0.07%	-0%
Net Income Growth %	-1.3%	-7.97%	2%	-2.73%	0.57%	0.69%	-0.7%	0.76%	-1.63%	0.92%
Net Income (Continuing)	-265.07M	-2.41B	2.4B	-4.14B	-1.78B	-559M	-937M	-212M	-611M	-72M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	119M	106M	95M	82M	73M	70M	72M	952M	940M	957M
EPS (Diluted)+	-0.77	-6.94	8.59	-11.86	-5.06	-1.57	-2.61	-0.59	-1.62	-0.13
EPS Growth %	-1.25%	-8.01%	2.24%	-2.38%	0.57%	0.69%	-0.66%	0.77%	-1.75%	0.92%
EPS (Basic)	-0.78	-6.94	8.63	-11.86	-5.06	-1.57	-2.61	-0.59	-1.62	-0.13
Diluted Shares Outstanding	347.3M	347.3M	351.8M	349.87M	352.1M	355M	358.9M	362M	364.9M	368M
Basic Shares Outstanding	342.7M	347.12M	350.2M	349.87M	352.1M	355M	358.9M	362M	365.43M	368M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.51B	5.08B	4.75B	723M	6.97B	5.34B	5.61B	4.25B	5.6B	5.77B
Cash & Short-Term Investments	597.3M	542M	720M	721M	3.24B	605M	582M	564M	947M	1.18B
Cash Only	597.3M	542M	720M	721M	3.24B	605M	582M	564M	947M	1.18B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.69B	2.52B	2.13B	1.86B	1.84B	1.58B	1.77B	1.79B	2B	2.14B
Days Sales Outstanding	93.92	94.97	89.12	81.23	78.04	71.71	76.82	80.42	83.28	81.15
Inventory	1.26B	1.06B	1.05B	934M	1.11B	1.09B	993M	1.09B	1.54B	1.59B
Days Inventory Outstanding	187.51	150.51	150.13	145.01	171.94	177.55	151.4	168.3	220.23	209.26
Other Current Assets	930.4M	261M	77M	2M	10M	1.22B	1.54B	39M	1.11B	858M
Total Non-Current Assets+	43.46B	38.45B	32.75B	28.28B	26.89B	25.86B	23.59B	21.44B	21.75B	20.75B
Property, Plant & Equipment	1.44B	1.31B	1.4B	1.35B	1.47B	1.57B	1.6B	1.6B	1.71B	1.78B
Fixed Asset Turnover	7.24x	7.37x	6.22x	6.19x	5.87x	5.12x	5.28x	5.08x	5.13x	5.41x
Goodwill	18.55B	15.79B	15.59B	13.14B	13.13B	13.04B	12.46B	11.55B	11.18B	11.09B
Intangible Assets	23.08B	18.88B	15.21B	12B	10.2B	8.45B	6.95B	5.8B	6.46B	5.55B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	223.7M	2.32B	111M	109M	411M	664M	340M	326M	307M	363M
Total Assets+	48.96B	43.53B	37.5B	27.45B	33.86B	31.2B	29.2B	25.69B	27.35B	26.52B
Asset Turnover	0.21x	0.22x	0.23x	0.31x	0.25x	0.26x	0.29x	0.32x	0.32x	0.36x
Asset Growth %	0.86%	-0.11%	-0.14%	-0.27%	0.23%	-0.08%	-0.06%	-0.12%	0.06%	-0.03%
Total Current Liabilities+	5.31B	3.61B	4.27B	3.84B	6.25B	4.91B	5.2B	3.94B	4.3B	6.75B
Accounts Payable	434M	324M	365M	411M	503M	337M	407M	521M	719M	656M
Days Payables Outstanding	64.76	45.96	52.29	63.81	78.13	54.69	62.05	80.44	102.55	86.07
Short-Term Debt	839M	1M	209M	228M	1.23B	0	0	432M	450M	2.67B
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	1.86B	1.1B	1.21B	946M	2.42B	2.75B	2.98B	1.34B	1.4B	1.33B
Current Ratio	1.04x	1.41x	1.11x	0.19x	1.12x	1.09x	1.08x	1.08x	1.30x	0.86x
Quick Ratio	0.80x	1.11x	0.87x	-0.06x	0.94x	0.86x	0.89x	0.80x	0.94x	0.62x
Cash Conversion Cycle	216.67	199.52	186.96	162.43	171.85	194.57	166.16	168.28	200.95	204.35
Total Non-Current Liabilities+	37.62B	36.66B	27.29B	25.84B	26.48B	25.68B	24.04B	21.48B	23.13B	20.09B
Long-Term Debt	30.27B	29.84B	25.23B	24.08B	24.66B	23.93B	22.65B	20.33B	21.94B	18.94B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	165M
Deferred Tax Liabilities	5.9B	5.43B	1.18B	885M	705M	528M	529M	202M	163M	128M
Other Non-Current Liabilities	1.46B	1.38B	870M	879M	1.11B	1.23B	855M	949M	1.03B	857.49M
Total Liabilities	42.94B	40.27B	31.55B	29.68B	32.73B	30.59B	29.24B	25.43B	27.43B	26.84B
Total Debt+	31.1B	29.85B	25.44B	24.3B	25.89B	23.93B	22.65B	20.77B	22.39B	21.83B
Net Debt	30.51B	29.3B	24.72B	23.58B	22.65B	23.32B	22.07B	20.2B	21.44B	20.63B
Debt / Equity	5.16x	9.16x	4.28x	8.63x	22.79x	39.55x	-	79.87x	-	-
Debt / EBITDA	7.79x	12.98x	8.60x	55.87x	13.83x	9.57x	11.32x	11.24x	10.05x	7.76x
Net Debt / EBITDA	7.64x	12.74x	8.35x	54.22x	12.10x	9.32x	11.02x	10.93x	9.63x	7.33x
Interest Coverage	0.98x	-0.31x	0.06x	-1.41x	-0.13x	0.44x	0.32x	0.31x	0.73x	1.11x
Total Equity+	6.03B	3.26B	5.94B	2.81B	1.14B	605M	-34M	260M	-82M	-322M
Equity Growth %	0.12%	-0.46%	0.82%	-0.53%	-0.6%	-0.47%	-1.06%	8.65%	-1.32%	-2.93%
Book Value per Share	17.36	9.38	16.90	8.05	3.23	1.70	-0.09	0.72	-0.22	-0.88
Total Shareholders' Equity	5.91B	3.15B	5.85B	2.73B	1.06B	535M	-106M	-692M	-1.02B	-1.28B
Common Stock	9.9B	10.04B	10.09B	10.12B	10.17B	10.23B	10.32B	10.39B	10.42B	10.49B
Retained Earnings	-2.75B	-5.13B	-2.73B	-5.66B	-7.45B	-8.01B	-8.96B	-9.19B	-9.78B	-9.82B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.54B	-2.11B	-1.9B	-2.14B	-2.09B	-2.13B	-1.92B	-2.06B	-1.88B	-2.18B
Minority Interest	119M	106M	95M	82M	73M	70M	72M	952M	940M	957M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.2B	2.09B	2.29B	1.5B	1.5B	1.11B	1.43B	-728M	1.03B	1.6B
Operating CF Margin %	0.21%	0.22%	0.26%	0.18%	0.17%	0.14%	0.17%	-0.09%	0.12%	0.17%
Operating CF Growth %	-0.04%	-0.05%	0.1%	-0.34%	0%	-0.26%	0.28%	-1.51%	2.42%	0.55%
Net Income	-287.8M	-2.41B	2.4B	-4.14B	-1.78B	-559M	-937M	-212M	-611M	-72M
Depreciation & Amortization	2.63B	2.87B	2.86B	2.82B	2.08B	1.82B	1.55B	1.39B	1.26B	1.27B
Stock-Based Compensation	140.1M	165M	87M	87M	102M	105M	128M	126M	132M	150M
Deferred Taxes	-7M	-236M	-4.39B	-144M	-230M	-475M	-225M	-176M	51M	66M
Other Non-Cash Items	549.8M	1.81B	483M	2.87B	1.66B	581M	1.04B	-1.46B	778M	179M
Working Capital Changes	-822.2M	-110M	844M	18M	-318M	-366M	-128M	-396M	-582M	7M
Change in Receivables	-625.9M	-34M	417M	216M	39M	170M	-229M	-57M	-195M	-216M
Change in Inventory	-276M	-164M	7M	-5M	-209M	-77M	-16M	-198M	-322M	-267M
Change in Payables	170.3M	-144M	387M	-568M	-149M	-471M	121M	-75M	158M	357M
Cash from Investing+	-15.58B	-125M	2.89B	-196M	-419M	-261M	409M	-303M	-2.15B	-454M
Capital Expenditures	-303.3M	-291M	-336M	-235M	-278M	-302M	-269M	-218M	-215M	-337M
CapEx % of Revenue	0.03%	0.03%	0.04%	0.03%	0.03%	0.04%	0.03%	0.03%	0.02%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-18.7M	199M	3.39B	34M	45M	37M	682M	-45M	-39M	-119M
Cash from Financing+	13.62B	-1.96B	-4.96B	-1.35B	1.44B	-2.29B	-1.51B	-474M	1.48B	-868M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-376M	-747M	-184M	-186M	-71M	-107M	-173M	-139M	-106M	-43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.9B	1.8B	1.95B	1.27B	1.22B	802M	1.14B	-996M	760M	1.26B
FCF Margin %	0.18%	0.19%	0.22%	0.15%	0.14%	0.1%	0.14%	-0.12%	0.09%	0.13%
FCF Growth %	0.04%	-0.05%	0.09%	-0.35%	-0.03%	-0.34%	0.43%	-1.87%	1.76%	0.66%
FCF per Share	5.46	5.17	5.55	3.62	3.47	2.26	3.18	-2.75	2.08	3.42
FCF Conversion (FCF/Net Income)	-8.19x	-0.87x	0.95x	-0.36x	-0.84x	-1.99x	-1.50x	3.24x	-1.74x	-34.72x
Interest Paid	1.27B	0	1.71B	0	0	0	0	1.54B	1.53B	1.67B
Taxes Paid	95M	0	179M	0	0	0	0	266M	237M	61M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-4.7%	-51.88%	52.25%	-94.71%	-90.26%	-64.22%	-332.05%	-199.12%	-665.17%	-
Return on Invested Capital (ROIC)	4.03%	-1.23%	0.24%	-6.27%	-0.61%	2.13%	1.47%	1.6%	3.45%	5.56%
Gross Margin	76.58%	73.4%	70.79%	71.95%	72.68%	71.98%	71.61%	70.9%	70.78%	71.1%
Net Margin	-2.57%	-24.9%	27.56%	-49.5%	-20.73%	-6.96%	-11.24%	-2.77%	-6.76%	-0.48%
Debt / Equity	5.16x	9.16x	4.28x	8.63x	22.79x	39.55x	-	79.87x	-	-
Interest Coverage	0.98x	-0.31x	0.06x	-1.41x	-0.13x	0.44x	0.32x	0.31x	0.73x	1.11x
FCF Conversion	-8.19x	-0.87x	0.95x	-0.36x	-0.84x	-1.99x	-1.50x	3.24x	-1.74x	-34.72x
Revenue Growth	27.34%	-7.35%	-9.82%	-3.94%	2.64%	-6.67%	5.07%	-3.68%	7.79%	9.91%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Pharmaceutical Products	6.09B	5.17B	4.38B	4.03B	-	-	-	-	3.91B	4.4B
Pharmaceutical Products Growth	-	-15.22%	-15.29%	-7.88%	-	-	-	-	-	12.46%
Device Products	1.49B	1.52B	1.53B	1.64B	-	-	-	-	2B	2.24B
Device Products Growth	-	1.57%	0.92%	7.05%	-	-	-	-	-	12.17%
Over the Counter Products	1.58B	1.58B	1.53B	1.41B	-	-	-	-	1.8B	1.9B
Over the Counter Products Growth	-	-0.12%	-3.29%	-7.65%	-	-	-	-	-	5.90%
Branded and Other Generic Products	1.12B	1.27B	1.16B	1.19B	-	-	-	-	960M	979M
Branded and Other Generic Products Growth	-	13.35%	-8.90%	2.59%	-	-	-	-	-	1.98%
Other Revenues	-	-	-	109M	-	-	-	-	94M	107M
Other Revenues Growth	-	-	-	-	-	-	-	-	-	13.83%
Product	-	-	-	-	8.49B	7.92B	8.34B	8.05B	-	-
Product Growth	-	-	-	-	-	-6.66%	5.28%	-3.55%	-	-
Product and Service, Other	-	-	-	-	112M	103M	92M	78M	-	-
Product and Service, Other Growth	-	-	-	-	-	-8.04%	-10.68%	-15.22%	-	-
Alliance and Royalty, Services and Other Products	154.3M	138M	129M	-	-	-	-	-	-	-
Alliance and Royalty, Services and Other Products Growth	-	-10.56%	-6.52%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States and Puerto Rico	7.06B	6.25B	5.22B	5.01B	5.16B	4.79B	4.89B	4.84B	5.19B	5.77B
United States and Puerto Rico Growth	-	-11.55%	-16.36%	-4.10%	3.05%	-7.22%	2.00%	-1.04%	7.40%	11.03%
Other Countries	1.25B	1.16B	1.17B	1.04B	995M	1.01B	986M	887M	1.01B	1.08B
Other Countries Growth	-	-7.47%	0.86%	-10.71%	-4.51%	1.31%	-2.18%	-10.04%	13.98%	7.12%
CHINA	271.5M	300M	331M	361M	368M	341M	490M	413M	441M	496M
CHINA Growth	-	10.50%	10.33%	9.06%	1.94%	-7.34%	43.70%	-15.71%	6.78%	12.47%
CANADA	333.6M	320M	326M	319M	339M	331M	343M	351M	366M	402M
CANADA Growth	-	-4.08%	1.88%	-2.15%	6.27%	-2.36%	3.63%	2.33%	4.27%	9.84%
POLAND	213.5M	140M	201M	218M	231M	238M	280M	278M	319M	350M
POLAND Growth	-	-34.43%	43.57%	8.46%	5.96%	3.03%	17.65%	-0.71%	14.75%	9.72%
MEXICO	203.9M	189M	201M	211M	228M	225M	256M	276M	322M	315M
MEXICO Growth	-	-7.31%	6.35%	4.98%	8.06%	-1.32%	13.78%	7.81%	16.67%	-2.17%
FRANCE	178.3M	186M	188M	205M	201M	179M	208M	203M	214M	230M
FRANCE Growth	-	4.32%	1.08%	9.04%	-1.95%	-10.95%	16.20%	-2.40%	5.42%	7.48%
JAPAN	206.4M	232M	223M	226M	241M	226M	230M	200M	194M	188M
JAPAN Growth	-	12.40%	-3.88%	1.35%	6.64%	-6.22%	1.77%	-13.04%	-3.00%	-3.09%
GERMANY	159.4M	157M	157M	170M	150M	144M	154M	147M	152M	159M
GERMANY Growth	-	-1.51%	0.00%	8.28%	-11.76%	-4.00%	6.94%	-4.55%	3.40%	4.61%
KOREA, REPUBLIC OF	-	-	-	-	-	-	-	77M	93M	146M
KOREA, REPUBLIC OF Growth	-	-	-	-	-	-	-	-	20.78%	56.99%
SPAIN	-	-	-	83M	86M	78M	88M	84M	92M	99M
SPAIN Growth	-	-	-	-	3.61%	-9.30%	12.82%	-4.55%	9.52%	7.61%
ITALY	-	-	-	85M	85M	-	80M	76M	86M	94M
ITALY Growth	-	-	-	-	0.00%	-	-	-5.00%	13.16%	9.30%
EGYPT	-	196M	152M	178M	218M	243M	156M	-	-	-
EGYPT Growth	-	-	-22.45%	17.11%	22.47%	11.47%	-35.80%	-	-	-
AUSTRALIA	182.3M	176M	149M	-	-	-	-	-	-	-
AUSTRALIA Growth	-	-3.46%	-15.34%	-	-	-	-	-	-	-
BRAZIL	110.2M	105M	96M	-	-	-	-	-	-	-
BRAZIL Growth	-	-4.72%	-8.57%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Bausch Health Companies Inc. (BHC) reported $8.26B in revenue for fiscal year 2024. This represents a 235% increase from $2.46B in 2011.

Bausch Health Companies Inc. (BHC) grew revenue by 9.9% over the past year. This is steady growth.

Yes, Bausch Health Companies Inc. (BHC) is profitable, generating $362.0M in net income for fiscal year 2024 (-0.5% net margin).

Dividend & Returns

Bausch Health Companies Inc. (BHC) generated $1.08B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Bausch Health Companies Inc. (BHC) 10-Year Financial Performance & Capital Metrics

BHC • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsMulti-Therapeutic Specialty

Revenue $9.63B +9.9%
EBITDA $2.81B +26.3%
Net Income -$46M +92.2%
EPS (Diluted) -0.13 +92.0%
Gross Margin 71.1% +0.4%
EBITDA Margin 29.23% +14.9%
Operating Margin 16.06% +46.1%
Net Margin -0.48% +92.9%
ROE -
ROIC 5.56% +61.1%
Debt/Equity -
Interest Coverage 1.11 +53.6%

Technical Analysis

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.62%

5Y2.28%

3Y4.5%

TTM-12.81%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM303.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM151.76%

ROCE

10Y Avg1.21%

5Y Avg3.56%

3Y Avg4.5%

Latest7.22%

Peer Comparison

Multi-Therapeutic Specialty

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BHCBausch Health Companies Inc.	2.69B	7.26	-55.85	9.91%	4.38%	101.78%	46.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	10.44B	9.67B	8.72B	8.38B	8.6B	8.03B	8.43B	8.12B	8.76B	9.63B
Revenue Growth %	0.27%	-0.07%	-0.1%	-0.04%	0.03%	-0.07%	0.05%	-0.04%	0.08%	0.1%
Cost of Goods Sold+	2.45B	2.57B	2.55B	2.35B	2.35B	2.25B	2.39B	2.36B	2.56B	2.78B
COGS % of Revenue	0.23%	0.27%	0.29%	0.28%	0.27%	0.28%	0.28%	0.29%	0.29%	0.29%
Gross Profit+	8B	7.1B	6.18B	6.03B	6.25B	5.78B	6.04B	5.76B	6.2B	6.84B
Gross Margin %	0.77%	0.73%	0.71%	0.72%	0.73%	0.72%	0.72%	0.71%	0.71%	0.71%
Gross Profit Growth %	0.33%	-0.11%	-0.13%	-0.02%	0.04%	-0.08%	0.05%	-0.05%	0.08%	0.1%
Operating Expenses+	6.47B	7.67B	6.07B	8.41B	6.45B	5.1B	5.59B	5.31B	5.24B	5.3B
OpEx % of Revenue	0.62%	0.79%	0.7%	1%	0.75%	0.64%	0.66%	0.65%	0.6%	0.55%
Selling, General & Admin	2.7B	2.78B	2.58B	2.47B	2.55B	2.37B	2.49B	2.53B	2.9B	3.28B
SG&A % of Revenue	0.26%	0.29%	0.3%	0.3%	0.3%	0.29%	0.3%	0.31%	0.33%	0.34%
Research & Development	440M	469M	369M	442M	516M	485M	473M	530M	604M	634M
R&D % of Revenue	0.04%	0.05%	0.04%	0.05%	0.06%	0.06%	0.06%	0.07%	0.07%	0.07%
Other Operating Expenses	3.33B	4.42B	3.12B	5.5B	3.38B	2.25B	2.63B	2.25B	1.74B	1.38B
Operating Income+	1.53B	-566M	102M	-2.38B	-203M	676M	450M	454M	963M	1.55B
Operating Margin %	0.15%	-0.06%	0.01%	-0.28%	-0.02%	0.08%	0.05%	0.06%	0.11%	0.16%
Operating Income Growth %	-0.24%	-1.37%	1.18%	-24.37%	0.91%	4.33%	-0.33%	0.01%	1.12%	0.61%
EBITDA+	3.99B	2.3B	2.96B	435M	1.87B	2.5B	2B	1.85B	2.23B	2.81B
EBITDA Margin %	0.38%	0.24%	0.34%	0.05%	0.22%	0.31%	0.24%	0.23%	0.25%	0.29%
EBITDA Growth %	0.1%	-0.42%	0.29%	-0.85%	3.3%	0.34%	-0.2%	-0.08%	0.21%	0.26%
D&A (Non-Cash Add-back)	2.47B	2.87B	2.86B	2.82B	2.08B	1.82B	1.55B	1.39B	1.26B	1.27B
EBIT	2.64B	1.21B	555M	500M	1.34B	1.31B	1.71B	1.48B	1.62B	1.87B
Net Interest Income+	-1.56B	-1.83B	-1.83B	-1.67B	-1.6B	-1.52B	-1.42B	-1.45B	-1.3B	-1.35B
Interest Income	3.3M	8M	12M	11M	12M	13M	7M	14M	26M	33M
Interest Expense	1.56B	1.84B	1.84B	1.69B	1.61B	1.53B	1.43B	1.46B	1.33B	1.39B
Other Income/Expense	-1.68B	-1.87B	-1.84B	-1.77B	-1.63B	-1.61B	-1.47B	-583M	-1.35B	-1.38B
Pretax Income+	-155M	-2.44B	-1.74B	-4.15B	-1.84B	-934M	-1.02B	-129M	-390M	167M
Pretax Margin %	-0.01%	-0.25%	-0.2%	-0.5%	-0.21%	-0.12%	-0.12%	-0.02%	-0.04%	0.02%
Income Tax+	133M	-27M	-4.14B	-10M	-54M	-375M	-87M	83M	221M	239M
Effective Tax Rate %	1.73%	0.99%	-1.38%	1%	0.97%	0.6%	0.93%	1.74%	1.52%	-0.28%
Net Income+	-268.66M	-2.41B	2.4B	-4.15B	-1.78B	-559M	-948M	-225M	-592M	-46M
Net Margin %	-0.03%	-0.25%	0.28%	-0.49%	-0.21%	-0.07%	-0.11%	-0.03%	-0.07%	-0%
Net Income Growth %	-1.3%	-7.97%	2%	-2.73%	0.57%	0.69%	-0.7%	0.76%	-1.63%	0.92%
Net Income (Continuing)	-265.07M	-2.41B	2.4B	-4.14B	-1.78B	-559M	-937M	-212M	-611M	-72M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	119M	106M	95M	82M	73M	70M	72M	952M	940M	957M
EPS (Diluted)+	-0.77	-6.94	8.59	-11.86	-5.06	-1.57	-2.61	-0.59	-1.62	-0.13
EPS Growth %	-1.25%	-8.01%	2.24%	-2.38%	0.57%	0.69%	-0.66%	0.77%	-1.75%	0.92%
EPS (Basic)	-0.78	-6.94	8.63	-11.86	-5.06	-1.57	-2.61	-0.59	-1.62	-0.13
Diluted Shares Outstanding	347.3M	347.3M	351.8M	349.87M	352.1M	355M	358.9M	362M	364.9M	368M
Basic Shares Outstanding	342.7M	347.12M	350.2M	349.87M	352.1M	355M	358.9M	362M	365.43M	368M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.51B	5.08B	4.75B	723M	6.97B	5.34B	5.61B	4.25B	5.6B	5.77B
Cash & Short-Term Investments	597.3M	542M	720M	721M	3.24B	605M	582M	564M	947M	1.18B
Cash Only	597.3M	542M	720M	721M	3.24B	605M	582M	564M	947M	1.18B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	2.69B	2.52B	2.13B	1.86B	1.84B	1.58B	1.77B	1.79B	2B	2.14B
Days Sales Outstanding	93.92	94.97	89.12	81.23	78.04	71.71	76.82	80.42	83.28	81.15
Inventory	1.26B	1.06B	1.05B	934M	1.11B	1.09B	993M	1.09B	1.54B	1.59B
Days Inventory Outstanding	187.51	150.51	150.13	145.01	171.94	177.55	151.4	168.3	220.23	209.26
Other Current Assets	930.4M	261M	77M	2M	10M	1.22B	1.54B	39M	1.11B	858M
Total Non-Current Assets+	43.46B	38.45B	32.75B	28.28B	26.89B	25.86B	23.59B	21.44B	21.75B	20.75B
Property, Plant & Equipment	1.44B	1.31B	1.4B	1.35B	1.47B	1.57B	1.6B	1.6B	1.71B	1.78B
Fixed Asset Turnover	7.24x	7.37x	6.22x	6.19x	5.87x	5.12x	5.28x	5.08x	5.13x	5.41x
Goodwill	18.55B	15.79B	15.59B	13.14B	13.13B	13.04B	12.46B	11.55B	11.18B	11.09B
Intangible Assets	23.08B	18.88B	15.21B	12B	10.2B	8.45B	6.95B	5.8B	6.46B	5.55B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	223.7M	2.32B	111M	109M	411M	664M	340M	326M	307M	363M
Total Assets+	48.96B	43.53B	37.5B	27.45B	33.86B	31.2B	29.2B	25.69B	27.35B	26.52B
Asset Turnover	0.21x	0.22x	0.23x	0.31x	0.25x	0.26x	0.29x	0.32x	0.32x	0.36x
Asset Growth %	0.86%	-0.11%	-0.14%	-0.27%	0.23%	-0.08%	-0.06%	-0.12%	0.06%	-0.03%
Total Current Liabilities+	5.31B	3.61B	4.27B	3.84B	6.25B	4.91B	5.2B	3.94B	4.3B	6.75B
Accounts Payable	434M	324M	365M	411M	503M	337M	407M	521M	719M	656M
Days Payables Outstanding	64.76	45.96	52.29	63.81	78.13	54.69	62.05	80.44	102.55	86.07
Short-Term Debt	839M	1M	209M	228M	1.23B	0	0	432M	450M	2.67B
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	1.86B	1.1B	1.21B	946M	2.42B	2.75B	2.98B	1.34B	1.4B	1.33B
Current Ratio	1.04x	1.41x	1.11x	0.19x	1.12x	1.09x	1.08x	1.08x	1.30x	0.86x
Quick Ratio	0.80x	1.11x	0.87x	-0.06x	0.94x	0.86x	0.89x	0.80x	0.94x	0.62x
Cash Conversion Cycle	216.67	199.52	186.96	162.43	171.85	194.57	166.16	168.28	200.95	204.35
Total Non-Current Liabilities+	37.62B	36.66B	27.29B	25.84B	26.48B	25.68B	24.04B	21.48B	23.13B	20.09B
Long-Term Debt	30.27B	29.84B	25.23B	24.08B	24.66B	23.93B	22.65B	20.33B	21.94B	18.94B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	165M
Deferred Tax Liabilities	5.9B	5.43B	1.18B	885M	705M	528M	529M	202M	163M	128M
Other Non-Current Liabilities	1.46B	1.38B	870M	879M	1.11B	1.23B	855M	949M	1.03B	857.49M
Total Liabilities	42.94B	40.27B	31.55B	29.68B	32.73B	30.59B	29.24B	25.43B	27.43B	26.84B
Total Debt+	31.1B	29.85B	25.44B	24.3B	25.89B	23.93B	22.65B	20.77B	22.39B	21.83B
Net Debt	30.51B	29.3B	24.72B	23.58B	22.65B	23.32B	22.07B	20.2B	21.44B	20.63B
Debt / Equity	5.16x	9.16x	4.28x	8.63x	22.79x	39.55x	-	79.87x	-	-
Debt / EBITDA	7.79x	12.98x	8.60x	55.87x	13.83x	9.57x	11.32x	11.24x	10.05x	7.76x
Net Debt / EBITDA	7.64x	12.74x	8.35x	54.22x	12.10x	9.32x	11.02x	10.93x	9.63x	7.33x
Interest Coverage	0.98x	-0.31x	0.06x	-1.41x	-0.13x	0.44x	0.32x	0.31x	0.73x	1.11x
Total Equity+	6.03B	3.26B	5.94B	2.81B	1.14B	605M	-34M	260M	-82M	-322M
Equity Growth %	0.12%	-0.46%	0.82%	-0.53%	-0.6%	-0.47%	-1.06%	8.65%	-1.32%	-2.93%
Book Value per Share	17.36	9.38	16.90	8.05	3.23	1.70	-0.09	0.72	-0.22	-0.88
Total Shareholders' Equity	5.91B	3.15B	5.85B	2.73B	1.06B	535M	-106M	-692M	-1.02B	-1.28B
Common Stock	9.9B	10.04B	10.09B	10.12B	10.17B	10.23B	10.32B	10.39B	10.42B	10.49B
Retained Earnings	-2.75B	-5.13B	-2.73B	-5.66B	-7.45B	-8.01B	-8.96B	-9.19B	-9.78B	-9.82B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.54B	-2.11B	-1.9B	-2.14B	-2.09B	-2.13B	-1.92B	-2.06B	-1.88B	-2.18B
Minority Interest	119M	106M	95M	82M	73M	70M	72M	952M	940M	957M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.2B	2.09B	2.29B	1.5B	1.5B	1.11B	1.43B	-728M	1.03B	1.6B
Operating CF Margin %	0.21%	0.22%	0.26%	0.18%	0.17%	0.14%	0.17%	-0.09%	0.12%	0.17%
Operating CF Growth %	-0.04%	-0.05%	0.1%	-0.34%	0%	-0.26%	0.28%	-1.51%	2.42%	0.55%
Net Income	-287.8M	-2.41B	2.4B	-4.14B	-1.78B	-559M	-937M	-212M	-611M	-72M
Depreciation & Amortization	2.63B	2.87B	2.86B	2.82B	2.08B	1.82B	1.55B	1.39B	1.26B	1.27B
Stock-Based Compensation	140.1M	165M	87M	87M	102M	105M	128M	126M	132M	150M
Deferred Taxes	-7M	-236M	-4.39B	-144M	-230M	-475M	-225M	-176M	51M	66M
Other Non-Cash Items	549.8M	1.81B	483M	2.87B	1.66B	581M	1.04B	-1.46B	778M	179M
Working Capital Changes	-822.2M	-110M	844M	18M	-318M	-366M	-128M	-396M	-582M	7M
Change in Receivables	-625.9M	-34M	417M	216M	39M	170M	-229M	-57M	-195M	-216M
Change in Inventory	-276M	-164M	7M	-5M	-209M	-77M	-16M	-198M	-322M	-267M
Change in Payables	170.3M	-144M	387M	-568M	-149M	-471M	121M	-75M	158M	357M
Cash from Investing+	-15.58B	-125M	2.89B	-196M	-419M	-261M	409M	-303M	-2.15B	-454M
Capital Expenditures	-303.3M	-291M	-336M	-235M	-278M	-302M	-269M	-218M	-215M	-337M
CapEx % of Revenue	0.03%	0.03%	0.04%	0.03%	0.03%	0.04%	0.03%	0.03%	0.02%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-18.7M	199M	3.39B	34M	45M	37M	682M	-45M	-39M	-119M
Cash from Financing+	13.62B	-1.96B	-4.96B	-1.35B	1.44B	-2.29B	-1.51B	-474M	1.48B	-868M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-376M	-747M	-184M	-186M	-71M	-107M	-173M	-139M	-106M	-43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.9B	1.8B	1.95B	1.27B	1.22B	802M	1.14B	-996M	760M	1.26B
FCF Margin %	0.18%	0.19%	0.22%	0.15%	0.14%	0.1%	0.14%	-0.12%	0.09%	0.13%
FCF Growth %	0.04%	-0.05%	0.09%	-0.35%	-0.03%	-0.34%	0.43%	-1.87%	1.76%	0.66%
FCF per Share	5.46	5.17	5.55	3.62	3.47	2.26	3.18	-2.75	2.08	3.42
FCF Conversion (FCF/Net Income)	-8.19x	-0.87x	0.95x	-0.36x	-0.84x	-1.99x	-1.50x	3.24x	-1.74x	-34.72x
Interest Paid	1.27B	0	1.71B	0	0	0	0	1.54B	1.53B	1.67B
Taxes Paid	95M	0	179M	0	0	0	0	266M	237M	61M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-4.7%	-51.88%	52.25%	-94.71%	-90.26%	-64.22%	-332.05%	-199.12%	-665.17%	-
Return on Invested Capital (ROIC)	4.03%	-1.23%	0.24%	-6.27%	-0.61%	2.13%	1.47%	1.6%	3.45%	5.56%
Gross Margin	76.58%	73.4%	70.79%	71.95%	72.68%	71.98%	71.61%	70.9%	70.78%	71.1%
Net Margin	-2.57%	-24.9%	27.56%	-49.5%	-20.73%	-6.96%	-11.24%	-2.77%	-6.76%	-0.48%
Debt / Equity	5.16x	9.16x	4.28x	8.63x	22.79x	39.55x	-	79.87x	-	-
Interest Coverage	0.98x	-0.31x	0.06x	-1.41x	-0.13x	0.44x	0.32x	0.31x	0.73x	1.11x
FCF Conversion	-8.19x	-0.87x	0.95x	-0.36x	-0.84x	-1.99x	-1.50x	3.24x	-1.74x	-34.72x
Revenue Growth	27.34%	-7.35%	-9.82%	-3.94%	2.64%	-6.67%	5.07%	-3.68%	7.79%	9.91%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Pharmaceutical Products	6.09B	5.17B	4.38B	4.03B	-	-	-	-	3.91B	4.4B
Pharmaceutical Products Growth	-	-15.22%	-15.29%	-7.88%	-	-	-	-	-	12.46%
Device Products	1.49B	1.52B	1.53B	1.64B	-	-	-	-	2B	2.24B
Device Products Growth	-	1.57%	0.92%	7.05%	-	-	-	-	-	12.17%
Over the Counter Products	1.58B	1.58B	1.53B	1.41B	-	-	-	-	1.8B	1.9B
Over the Counter Products Growth	-	-0.12%	-3.29%	-7.65%	-	-	-	-	-	5.90%
Branded and Other Generic Products	1.12B	1.27B	1.16B	1.19B	-	-	-	-	960M	979M
Branded and Other Generic Products Growth	-	13.35%	-8.90%	2.59%	-	-	-	-	-	1.98%
Other Revenues	-	-	-	109M	-	-	-	-	94M	107M
Other Revenues Growth	-	-	-	-	-	-	-	-	-	13.83%
Product	-	-	-	-	8.49B	7.92B	8.34B	8.05B	-	-
Product Growth	-	-	-	-	-	-6.66%	5.28%	-3.55%	-	-
Product and Service, Other	-	-	-	-	112M	103M	92M	78M	-	-
Product and Service, Other Growth	-	-	-	-	-	-8.04%	-10.68%	-15.22%	-	-
Alliance and Royalty, Services and Other Products	154.3M	138M	129M	-	-	-	-	-	-	-
Alliance and Royalty, Services and Other Products Growth	-	-10.56%	-6.52%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States and Puerto Rico	7.06B	6.25B	5.22B	5.01B	5.16B	4.79B	4.89B	4.84B	5.19B	5.77B
United States and Puerto Rico Growth	-	-11.55%	-16.36%	-4.10%	3.05%	-7.22%	2.00%	-1.04%	7.40%	11.03%
Other Countries	1.25B	1.16B	1.17B	1.04B	995M	1.01B	986M	887M	1.01B	1.08B
Other Countries Growth	-	-7.47%	0.86%	-10.71%	-4.51%	1.31%	-2.18%	-10.04%	13.98%	7.12%
CHINA	271.5M	300M	331M	361M	368M	341M	490M	413M	441M	496M
CHINA Growth	-	10.50%	10.33%	9.06%	1.94%	-7.34%	43.70%	-15.71%	6.78%	12.47%
CANADA	333.6M	320M	326M	319M	339M	331M	343M	351M	366M	402M
CANADA Growth	-	-4.08%	1.88%	-2.15%	6.27%	-2.36%	3.63%	2.33%	4.27%	9.84%
POLAND	213.5M	140M	201M	218M	231M	238M	280M	278M	319M	350M
POLAND Growth	-	-34.43%	43.57%	8.46%	5.96%	3.03%	17.65%	-0.71%	14.75%	9.72%
MEXICO	203.9M	189M	201M	211M	228M	225M	256M	276M	322M	315M
MEXICO Growth	-	-7.31%	6.35%	4.98%	8.06%	-1.32%	13.78%	7.81%	16.67%	-2.17%
FRANCE	178.3M	186M	188M	205M	201M	179M	208M	203M	214M	230M
FRANCE Growth	-	4.32%	1.08%	9.04%	-1.95%	-10.95%	16.20%	-2.40%	5.42%	7.48%
JAPAN	206.4M	232M	223M	226M	241M	226M	230M	200M	194M	188M
JAPAN Growth	-	12.40%	-3.88%	1.35%	6.64%	-6.22%	1.77%	-13.04%	-3.00%	-3.09%
GERMANY	159.4M	157M	157M	170M	150M	144M	154M	147M	152M	159M
GERMANY Growth	-	-1.51%	0.00%	8.28%	-11.76%	-4.00%	6.94%	-4.55%	3.40%	4.61%
KOREA, REPUBLIC OF	-	-	-	-	-	-	-	77M	93M	146M
KOREA, REPUBLIC OF Growth	-	-	-	-	-	-	-	-	20.78%	56.99%
SPAIN	-	-	-	83M	86M	78M	88M	84M	92M	99M
SPAIN Growth	-	-	-	-	3.61%	-9.30%	12.82%	-4.55%	9.52%	7.61%
ITALY	-	-	-	85M	85M	-	80M	76M	86M	94M
ITALY Growth	-	-	-	-	0.00%	-	-	-5.00%	13.16%	9.30%
EGYPT	-	196M	152M	178M	218M	243M	156M	-	-	-
EGYPT Growth	-	-	-22.45%	17.11%	22.47%	11.47%	-35.80%	-	-	-
AUSTRALIA	182.3M	176M	149M	-	-	-	-	-	-	-
AUSTRALIA Growth	-	-3.46%	-15.34%	-	-	-	-	-	-	-
BRAZIL	110.2M	105M	96M	-	-	-	-	-	-	-
BRAZIL Growth	-	-4.72%	-8.57%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Bausch Health Companies Inc. (BHC) reported $8.26B in revenue for fiscal year 2024. This represents a 235% increase from $2.46B in 2011.

Bausch Health Companies Inc. (BHC) grew revenue by 9.9% over the past year. This is steady growth.

Yes, Bausch Health Companies Inc. (BHC) is profitable, generating $362.0M in net income for fiscal year 2024 (-0.5% net margin).

Dividend & Returns

Bausch Health Companies Inc. (BHC) generated $1.08B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.